ArticleFrontiers in oncology2026
Primary malignant melanoma of the uterine cervix: a case report of aggressive progression despite multimodal therapy.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case Report: Primary malignant melanoma of the uterine cervix with early recurrence following radical surgery and immunotherapy.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Primary malignant melanoma of the uterine cervix is an exceptionally rare malignancy with a biology distinct from its cutaneous counterpart and a dire prognosis. This case provides a critical Methods: We report a case of a 73-year-old woman with early-stage (pT1aN0), NRAS Q61K-mutant primary cervical melanoma. Results: The patient progressed rapidly through radical surgery and adjuvant Toripalimab (anti-PD-1) immunotherapy. Despite salvage therapy with a MEK inhibitor, she succumbed to the disease 17 months after diagnosis. The sequential failure of both immune checkpoint blockade and targeted pathway inhibition highlights a dual-layer of resistance. Conclusions: This experience mandates a fundamental re-evaluation of adjuvant strategies for this disease. It provides a compelling rationale for upfront, biology-driven combination trials (e.g., immunotherapy plus MEK or CDK4/6 inhibition) in the neoadjuvant or adjuvant setting for high-risk cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.